A workflow for global sensitivity analysis of PBPK models

被引:87
作者
McNally, Kevin [1 ]
Cotton, Richard [1 ]
Loizou, George D. [1 ]
机构
[1] Hlth & Safety Lab, Math Sci Unit, Buxton SK17 9JN, Derby, England
关键词
PBPK; global sensitivity analysis; alternatives; Lowry plot; TOXICOLOGICAL RISK-EVALUATION; PHARMACOKINETIC MODELS; TOXICITY; METABOLISM; UNCERTAINTY; VARIABILITY; CLEARANCE; EXPOSURE; VALUES; XYLENE;
D O I
10.3389/fphar.2011.00031
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Physiologically based pharmacokinetic (PBPK) models have a potentially significant role in the development of a reliable predictive toxicity testing strategy. The structure of PBPK models are ideal frameworks into which disparate in vitro and in vivo data can be integrated and utilized to translate information generated, using alternative to animal measures of toxicity and human biological monitoring data, into plausible corresponding exposures. However, these models invariably include the description of well known non-linear biological processes such as, enzyme saturation and interactions between parameters such as, organ mass and body mass. Therefore, an appropriate sensitivity analysis (SA) technique is required which can quantify the influences associated with individual parameters, interactions between parameters and any non-linear processes. In this report we have defined the elements of a workflow for SA of PBPK models that is computationally feasible, accounts for interactions between parameters, and can be displayed in the form of a bar chart and cumulative sum line (Lowry plot), which we believe is intuitive and appropriate for toxicologists, risk assessors, and regulators.
引用
收藏
页数:22
相关论文
共 54 条
  • [1] PHYSIOLOGICALLY-BASED PHARMACOKINETICS CANCER RISK ASSESSMENT
    ANDERSEN, ME
    KRISHNAN, K
    [J]. ENVIRONMENTAL HEALTH PERSPECTIVES, 1994, 102 : 103 - 108
  • [2] Toxicokinetic modeling and its applications in chemical risk assessment
    Andersen, ME
    [J]. TOXICOLOGY LETTERS, 2003, 138 (1-2) : 9 - 27
  • [3] [Anonymous], 2000, Probability and Statistics series
  • [4] [Anonymous], 2007, Toxicity testing in the 21st century : a vision and a strategy
  • [5] Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data:: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver
    Barter, Zoe E.
    Bayliss, Martin K.
    Beaune, Philip H.
    Boobis, Alan R.
    Carlile, David J.
    Edwards, Robert J.
    Houston, J. Brian
    Lake, Brian G.
    Lipscomb, John C.
    Pelkonen, Olavi R.
    Tucker, Geoffrey T.
    Rostami-Hodjegan, Amin
    [J]. CURRENT DRUG METABOLISM, 2007, 8 (01) : 33 - 45
  • [6] Barton H. A., 2009, IPCS PROJECT HARMONI
  • [7] Harmonization: Developing consistent guidelines for applying mode of action and dosimetry information to cancer and noncancer risk assessment
    Barton, HA
    Andersen, ME
    Clewell, HJ
    [J]. HUMAN AND ECOLOGICAL RISK ASSESSMENT, 1998, 4 (01): : 75 - 115
  • [8] Characterizing uncertainty and variability in physiologically based pharmacokinetic models: State of the science and needs for research and implementation
    Barton, Hugh A.
    Chiu, Weihsueh A.
    Setzer, R. Woodrow
    Andersen, Melvin E.
    Bailer, A. John
    Bois, Frederic Y.
    DeWoskin, Robert S.
    Hays, Sean
    Johanson, Gunnar
    Jones, Nancy
    Loizou, George
    MacPhail, Robert C.
    Portier, Christopher J.
    Spendiff, Martin
    Tan, Yu-Mei
    [J]. TOXICOLOGICAL SCIENCES, 2007, 99 (02) : 395 - 402
  • [9] BIOKINETIC MODELING AND IN VITRO-IN VIVO EXTRAPOLATIONS
    Blaauboer, Bas J.
    [J]. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS, 2010, 13 (2-4): : 242 - 252
  • [10] The necessity of biokinetic information in the interpretation of in vitro toxicity data
    Blaauboer, BJ
    [J]. ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2002, 30 : 85 - 91